This drug, with promising results for NASH-related biomarkers, 55 is under evaluation in a phase 2 study (SYNERGY-NASH, NCT04166773), with the primary outcome being the absence of NASH and no worsening of fibrosis on liver histology after 1 year of treatment
"With the recent success of GLP-1s, we believe Eli Lilly, Novo Nordisk and others have the opportunity to expand into categories far beyond what most investors are currently contemplating," Goldman said
Gastric Sleeve vs Semaglutide and Phentermine: Comparing Long-Term Results A gastric sleeve physically reduces the size of your stomach, which changes hunger hormone production at the source rather than relying on a medication you have to keep taking indefinitely
The balance of the carnitine pool is essential for maintaining organ function and is a promising target for the intervention and treatment of diseases
in some embodiments, the gel formulation also has an immediate or rapid release component for delivery of the active agent to the desired target site
In discussing the role GSTs with patients, I often refer to them as matchmakers that introduce glutathione to toxins